Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

The clinical utility of histone/protein deacetylase (HDAC) inhibitors in combinatorial regimens with proteasome inhibitors for patients with relapsed and refractory multiple myeloma (MM) is often limited by excessive toxicity due to HDAC inhibitor promiscuity with multiple HDACs. Therefore, more sel...

Descripción completa

Detalles Bibliográficos
Autores principales: Mostofa, AGM, Distler, Allison, Meads, Mark B., Sahakian, Eva, Powers, John J., Achille, Alexandra, Noyes, David, Wright, Gabriela, Fang, Bin, Izumi, Victoria, Koomen, John, Rampakrishnan, Rupal, Nguyen, Tuan P., De Avila, Gabriel, Silva, Ariosto S., Sudalagunta, Praneeth, Canevarolo, Rafael Renatino, Siqueira Silva, Maria D. Coelho, Alugubelli, Raghunandan Reddy, Dai, Hongyue A., Kulkarni, Amit, Dalton, William S., Hampton, Oliver A., Welsh, Eric A., Teer, Jamie K., Tungesvik, Alexandre, Wright, Kenneth L., Pinilla-Ibarz, Javier, Sotomayor, Eduardo M., Shain, Kenneth H., Brayer, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783683/
https://www.ncbi.nlm.nih.gov/pubmed/34793338
http://dx.doi.org/10.1172/jci.insight.151713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783683/
https://www.ncbi.nlm.nih.gov/pubmed/34793338
http://dx.doi.org/10.1172/jci.insight.151713

Ejemplares similares